CTXR
Citius Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−2.38%Year over year
Reported trailing growth
- Revenue
- +4456.8%
- EBITDA
- -39.8%
- EBIT
- -49.2%
- EPS
- +57.5%
- Free cash flow
- -69.4%
- Operating cash flow
- -69.4%
Forward estimates
Based on analyst estimates
- Revenue
- +148.7%
- EBITDA
- +41.3%
- EPS
- +26.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- +1.1%
- EBIT
- +8.3%
- Net income
- +4.4%
- EPS
- +43.4%
- Free cash flow
- +5.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026